Product Information
VRAYLAR 3 MG CAPSULE is a brand product labeled by Allergan, Inc., priced at $50.8839 per EA under NDC 61874013020. Its NADAC has been published 486 times since Jun 14, 2017.
FDA first approved this application on Sep 17, 2015.
Strength
3 mg/1
Manufacturer
Allergan, Inc.NDC
61874013020
Classification
Brand
Dosage Form
CAPSULE, GELATIN COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CARIPRAZINEApproval Type
New Drug (NDA)
FDA Application
NDA204370FDA Approved
9/17/2015
On Market Since
9/17/2015
Pharmacological Classes
Price Statistics
The NADAC for VRAYLAR 3 MG CAPSULE has been published 486 times since Jun 14, 2017, and over the history we have for it it has risen 45.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $50.8839 per EA |
|---|---|
| All-time high | $50.9560 (May 13, 2026) |
| All-time low | $34.9242 (Jun 14, 2017) |
| 52-week high | $50.9560 |
| 52-week low | $48.5114 |
| Median price | $41.9408 |
| Average price | $42.3749 |
| Largest weekly change | +9.5% (Jan 10, 2018) |
| Weeks tracked | 486 |
| Tracking since | Jun 14, 2017 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Allergan, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
cariprazine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VRAYLAR 3 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for VRAYLAR 3 MG CAPSULE, manufactured by Allergan, Inc., is $50.8839 per EA (NDC 61874013020), effective Sep 30, 2026.
How has the price of VRAYLAR 3 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for VRAYLAR 3 MG CAPSULE has risen 45.7%. It has been tracked across 486 weekly CMS publications since Jun 14, 2017.
What are the highest and lowest recorded NADAC prices for VRAYLAR 3 MG CAPSULE?
Since Jun 14, 2017, the NADAC for VRAYLAR 3 MG CAPSULE has ranged from a low of $34.9242 (Jun 14, 2017) to a high of $50.9560 (May 13, 2026), with a median of $41.9408 per EA.
Are there cheaper alternatives to VRAYLAR 3 MG CAPSULE?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as VRAYLAR 3 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures VRAYLAR 3 MG CAPSULE?
VRAYLAR 3 MG CAPSULE (NDC 61874013020) is labeled by Allergan, Inc., and CMS classifies it as a brand product.